Rivastigmine — Membership Pricing

Other medications in Neurological

• Rizatriptan
• Ropinirole
• Rufinamide
• Selegiline
• Siponimod
• Sumatriptan
• Teriflunomide
• Tiagabine

What Rivastigmine is approved for (FDA label)

Rivastigmine transdermal system is an acetylcholinesterase inhibitor indicated for treatment of: Mild, moderate, and severe dementia of the Alzheimer's type (AD) ( 1.1 ) Mild-to-moderate dementia associated with Parkinson's disease (PD) ( 1.2 ) 1.1 Alzheimer’s Disease Rivastigmine transdermal system is indicated for the treatment of dementia of the Alzheimer's type (AD). Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer's disease. 1.2 Parkinson’s Disease Dementia Rivastigmine transdermal system is indicated for the treatment of mild-to-moderate dementia associated with Parkinson's disease (PDD).

Source: Read the full FDA label on DailyMed. Label effective date: November 14, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Rivastigmine (FDA label)

Rivastigmine Transdermal System : 4.6 mg/24 hours or 9.5 mg/24 hours or 13.3 mg/24 hours ( 3 ) Rivastigmine transdermal system is available in 3 strengths. Each transdermal system has a beige backing layer labeled as either: Rivastigmine transdermal system 4.6 mg/24 hours, "Rivastigmine Transdermal System 4.6 mg/24 hours" Rivastigmine transdermal system 9.5 mg/24 hours, "Rivastigmine Transdermal System 9.5 mg/24 hours" Rivastigmine transdermal system 13.3 mg/24 hours, "Rivastigmine Transdermal System 13.3 mg/24 hours"

Source: FDA prescribing information (DailyMed). Set ID: 8b809739-8381-4cc1-ab4a-5b17ab902a3d. SPL document ID: eb0de734-0cf3-4e83-b14e-feebe76390e0. Label effective date: November 14, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Rivastigmine (FDA label)

Most common adverse reactions (less than 5% and higher than with placebo): Nausea, vomiting, and diarrhea. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Northstar Rx LLC at 1-800-206-7821 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Source: FDA prescribing information (DailyMed). Set ID: 8b809739-8381-4cc1-ab4a-5b17ab902a3d. SPL document ID: eb0de734-0cf3-4e83-b14e-feebe76390e0. Label effective date: November 14, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Rivastigmine (FDA label)

Known hypersensitivity to rivastigmine, other carbamate derivatives, or other components of the formulation. ( 4 ) History of application-site reactions with rivastigmine transdermal system suggestive of allergic contact dermatitis. ( 4 , 6.2 ) Rivastigmine transdermal system is contraindicated in patients with: known hypersensitivity to rivastigmine, other carbamate derivatives, or other components of the formulation [see Description ( 11 )] . previous history of application-site reactions with rivastigmine transdermal system suggestive of allergic contact dermatitis [see Warnings and Precautions ( 5.3 )] . Isolated cases of generalized skin reactions have been described in postmarketing experience [see Adverse Reactions ( 6.2 )] .

Source: FDA prescribing information (DailyMed). Set ID: 8b809739-8381-4cc1-ab4a-5b17ab902a3d. SPL document ID: eb0de734-0cf3-4e83-b14e-feebe76390e0. Label effective date: November 14, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Rivastigmine (FDA label)

Hospitalization and, rarely, death have been reported due to application of multiple transdermal systems at same time. Ensure patients or caregivers receive instruction on proper dosing and administration. ( 5.1 ) Gastrointestinal Adverse Reactions : May include significant nausea, vomiting, diarrhea, anorexia/decreased appetite, and weight loss, and may necessitate treatment interruption. Dehydration may result from prolonged vomiting or diarrhea and can be associated with serious outcomes. ( 5.2 ) Application-site reactions may occur with the transdermal system form of rivastigmine.

Source: FDA prescribing information (DailyMed). Set ID: 8b809739-8381-4cc1-ab4a-5b17ab902a3d. SPL document ID: eb0de734-0cf3-4e83-b14e-feebe76390e0. Label effective date: November 14, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Rivastigmine (FDA label)

Concomitant use with metoclopramide, beta-blockers, or cholinomimetics and anticholinergic medications is not recommended. ( 7.1 , 7.2 , 7.3 ) 7.1 Metoclopramide Due to the risk of additive extra-pyramidal adverse reactions, the concomitant use of metoclopramide and rivastigmine transdermal system is not recommended. 7.2 Cholinomimetic and Anticholinergic Medications Rivastigmine transdermal system may increase the cholinergic effects of other cholinomimetic medications and may also interfere with the activity of anticholinergic medications (e.g., oxybutynin, tolterodine). Concomitant use of rivastigmine transdermal system with medications having these pharmacologic effects is not recommended unless deemed clinically necessary [see Warnings and Precautions ( 5.5 )]. 7.3 Beta-Blockers Additive bradycardic effects resulting in syncope may occur when rivastigmine is used concomitantly with beta-blockers, especially cardioselective beta-blockers (including atenolol). Concomitant use is not recommended when signs of bradycardia including syncope are present.

Source: FDA prescribing information (DailyMed). Set ID: 8b809739-8381-4cc1-ab4a-5b17ab902a3d. SPL document ID: eb0de734-0cf3-4e83-b14e-feebe76390e0. Label effective date: November 14, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.